HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Increasing oestrogen receptor (ER) level in breast cancer is associated with more favourable prognostic parameters and with improved survival, according to an analysis of the Nottingham cohort over a ...

The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...

After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression ...

Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that ...